# A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

> **NCT06395753** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Debiopharm International SA** · enrollment: 66 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Debio 4228

## Key facts

- **NCT ID:** NCT06395753
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-23
- **Primary completion:** 2026-12
- **Final completion:** 2027-01
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06395753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06395753, "A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06395753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*